TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39222391
Drug: Rectal enema
Normalized name: Fleet Rectal Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal enema
Study: 39222391
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (oral preparation and rectal enema)
Study: 39222513
Drug: OC-Auto FIT
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-Auto FIT (threshold >100 ng/mL)
Study: 39222896
Drug: TEER group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEER group (TriClip System + medical therapy)
Study: 39222964
Drug: DOT Diary
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOT Diary (automated directly observed therapy app)
Study: 39223302
Drug: Insufflation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insufflation of carbon dioxide (CO2) during laparoscopic surgery, specific dosage and duration not mentioned
Study: 39223504
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous Zoledronic acid (ZOL)
Study: 39223526
Drug: Nebulized N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized N-acetylcysteine (NAC) therapy over 12 weeks
Study: 39223545
Drug: Raltitrexed (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed (3 mg/m²) plus Irinotecan
Study: 39223617
Drug: modified prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified prolonged exposure therapy (mPE) + treatment as usual (TAU)
Study: 39223617
Drug: modified prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified prolonged exposure therapy (mPE)
Study: 39223953
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy sessions
Study: 39224580
Drug: Pharmacopuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacopuncture therapy (PPT)
Study: 39224811
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with paclitaxel (50 mg/m2) and carboplatin (AUC=2) followed by concurrent CRT with the same regimen, radiation dose of 40 Gy over 16 fractions (2.5 Gray/fraction).
Study: 39224901
Drug: CMAB015 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMAB015 (150 mg)
Study: 39225259
Drug: Plozasiran 25
Normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plozasiran 25 mg
Study: 39225259
Drug: Plozasiran 50
Normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plozasiran 50 mg
Study: 39225259
Drug: Plozasiran (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plozasiran (both doses)
Study: 39225258
Drug: Edoxaban monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban monotherapy
Study: 39225258
Drug: Dual antithrombotic
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antithrombotic therapy (edoxaban plus a single antiplatelet agent)
Study: 39225267
Drug: Asundexian 50
Normalized name: Asundexian
DrugBank: Asundexian (DB19088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asundexian 50 mg once daily
Study: 39225267
Drug: Apixaban (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (standard dose)
Study: 39225278
Drug: Finerenone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone (20 mg or 40 mg once daily)
Study: 39225670
Drug: Acamprosate (666
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (666 mg dose 3 times daily)
Study: 39226247
Drug: CS-ADL (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-ADL (Cognitive Stimulation in Activities of Daily Living)
Study: 39226288
Drug: β-alanine supplementation
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-alanine supplementation (5g per dosage, total 155g over 7 days)
Study: 39226292
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Tamoxifen (LDT) at 10 mg every other day
Study: 39226292
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Tamoxifen (LDT) + Intermittent caloric restriction (ICR)
Study: 39226514
Drug: Trimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodality therapy (radiation with radiosensitizing chemotherapy)
Study: 39226704
Drug: Intraosseous (IO)
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous (IO) administration of 2-g TXA prehospital bolus; 11 participants
Study: 39226704
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of 2-g TXA prehospital bolus; 334 participants
Study: 39226704
Drug: Intraosseous (IO)
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous (IO) administration of 1-g TXA prehospital bolus followed by 1-g TXA infusion in-hospital over 8 hours; 13 participants
Study: 39226704
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of 1-g TXA prehospital bolus followed by 1-g TXA infusion in-hospital over 8 hours; 299 participants
Study: 39226719
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TRE and LCD (TRE + LCD)
Study: 39227453
Drug: CC or
Normalized name: BD Syringe 10cc Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC or CT genotypes
Study: 39227508
Drug: ESK981 160
Normalized name: ESK981
DrugBank: ESK981 (DB18155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESK981 160 mg once daily for 5 days per week for 4 weeks per cycle
Study: 39227583
Drug: Neoadjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pembrolizumab (200 mg IV) every three weeks for two cycles
Study: 39227626
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D adequate (> 30 ng/mL)
Study: 39227818
Drug: FOS-fructans (2.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS-fructans (2.1 g/day)
Study: 39227818
Drug: Gluten (5.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten (5.7 g/day)
Study: 39227921
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LCD and TRE
Study: 39228131
Drug: Artesunate-amodiaquine (200/540
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-amodiaquine (200/540 mg daily for 3 days)
Study: 39228131
Drug: Dihydroartemisinin-piperaquine (40/960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (40/960 mg daily for 3 days)
Study: 39229259
Drug: All vaccine
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccine combinations
Study: 39229468
Drug: Dalpiciclib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib (150 mg) plus letrozole/anastrozole
Study: 39229468
Drug: Dalpiciclib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib (150 mg) plus fulvestrant
Study: 39229468
Drug: Dalpiciclib (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib (175 mg) plus letrozole/anastrozole
Study: 39229468
Drug: Dalpiciclib (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib (175 mg) plus fulvestrant
Study: 39229468
Drug: Dalpiciclib (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib (lower doses) plus letrozole/anastrozole
Study: 39229468
Drug: Dalpiciclib (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib (lower doses) plus fulvestrant
Study: 39230545
Drug: CSL112 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (6 g, 4 weekly infusions)
Study: 39230829
Drug: 350/700 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350/700 mg BAM + ETE
Study: 39230885
Drug: Aficamten (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aficamten (5-20 mg daily)
Study: 39231342
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of Lu AG09222
Study: 39231855
Drug: Nofazinlimab 200
Normalized name: Nofazinlimab
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nofazinlimab 200 mg every 3 weeks (Q3W)
Study: 39231898
Drug: Angiotensin-(1-7) infusion
Normalized name: Angiotensin (1-7)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-(1-7) infusion at 10 mcg/Kg day for a maximum of 7 days (Phase 2)
Study: 39232408
Drug: nab-paclitaxel (nab-P)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel (nab-P) 100 mg/m² on days 1 and 8, carboplatin (C) on day 1, every 3 weeks for 6 cycles
Study: 39232496
Drug: CMG901 (Claudin18.2-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMG901 (Claudin18.2-specific antibody-drug conjugate)
Study: 39232602
Drug: Spirulina (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (1 g twice daily for 14 days)
Study: 39232634
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 to 150 mg every 2 weeks subcutaneously
Study: 39232760
Drug: Shoulder massage
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shoulder massage administered twice at 6-hour intervals
Study: 39232761
Drug: Fuzuloparib 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzuloparib 60 mg BID plus mFOLFIRINOX q2w for 8-12 cycles followed by maintenance fuzuloparib at 150 mg BID
Study: 39232761
Drug: Fuzuloparib 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzuloparib 30 mg BID
Study: 39232761
Drug: Fuzuloparib 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzuloparib 60 mg BID
Study: 39232761
Drug: Fuzuloparib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzuloparib 100 mg BID
Study: 39232792
Drug: Multicomponent physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent physical training programme (progressive and supervised endurance, resistance and balance training for 4 weeks, twice weekly sessions, total of 8 sessions)
Study: 39232999
Drug: Adjunctive pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive pneumatic compression
Study: 39233312
Drug: Belzutifan 200
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan 200 mg once daily
Study: 39234416
Drug: Benralizumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab (30 mg each) administered subcutaneously every 4 weeks (n=9)
Study: 39235513
Drug: sodium hypochlorite/amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium hypochlorite/amino acid gel and crosslinked hyaluronic acid (xHyA) with subgingival instrumentation
Study: 39235596
Drug: Sitravatinib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitravatinib monotherapy
Study: 39235596
Drug: Sitravatinib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitravatinib monotherapy and sitravatinib plus tislelizumab
Study: 39235772
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg daily for 8 weeks
Study: 39235853
Drug: SteWARdS Antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: SteWARdS Antibiotic Defence app (intervention group)
Study: 39236733
Drug: Casirivimab and
Normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Casirivimab and imdevimab (150-1200 mg intravenously or 600-1200 mg subcutaneously) administered before or at the same time as mRNA-1273 vaccination
Study: 39236733
Drug: Casirivimab and
Normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Casirivimab and imdevimab administered 48 mg and 12 mg intravenously
Study: 39236733
Drug: mRNA-1273 administered
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 administered 6 days before mAb
Study: 39236736
Drug: IIS (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIS (10 mg/kg infliximab)
Study: 39236736
Drug: AIS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIS (5 mg/kg infliximab, accelerated induction)
Study: 39236736
Drug: SIS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIS (5 mg/kg infliximab, standard induction)
Study: 39236984
Drug: Isotoxically dose-escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotoxically dose-escalated chemoradiotherapy (60-74 Gy in 30-37 fractions)
Study: 39237135
Drug: Product A
Normalized name: Vaccine product against severe acute respiratory syndrome coronavirus 2 (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product A (iso-osmolar dose)
Study: 39237135
Drug: Product B
Normalized name: Product base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product B (iso-osmolar escalation dose)
Study: 39237135
Drug: Product C
Normalized name: Product containing plant agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product C (hypo-osmolar escalation dose)
Study: 39237158
Drug: Standard CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CT scan with intravenous contrast
Study: 39237273
Drug: Digital therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital therapy programme using a smartphone application based on individual health data, duration of 180 days (90-day in-life phase followed by a 90-day follow-up phase).
Study: 39237273
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for the treatment of primary arterial hypertension, duration of 180 days.
Study: 39237283
Drug: Standardised intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised intervention for announcing decisions of withholding or withdrawing life-sustaining treatments
Study: 39237427
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg orally daily from days 1 to 21; Daratumumab 16 mg/kg intravenously on specified days; Dexamethasone 40 mg (age ≤ 75 years) or 20 mg (age > 75 years) orally on specified days.
Study: 39238363
Drug: Monthly linear
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly linear decrease in QMNC index over time
Study: 39239277
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with docetaxel and cisplatin (TP) followed by radiation.
Study: 39239277
Drug: TP plus
Normalized name: Unifine Pentp Plus 4mm x 33g
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP plus PD-1 inhibition by pembrolizumab (MK-3475; 200 mg i.v. starting day 1 q3w for 17 cycles).
Study: 39240567
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg twice daily for 3 days, then 0.5 mg daily thereafter)
Study: 39241203
Drug: Nivolumab 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m² for four cycles
Study: 39241203
Drug: Nivolumab 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m² for four cycles (including reTURBT)
Study: 39241211
Drug: Imlunestrant monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imlunestrant monotherapy (n = 114)
Study: 39241211
Drug: Imlunestrant +
Normalized name: Imlunestrant
DrugBank: Imlunestrant (DB19043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imlunestrant + abemaciclib + aromatase inhibitor (AI) (n = 43)
Study: 39241341
Drug: Classical massage
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical massage (MG)
Study: 39241828
Drug: 72-hr octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72-hr octreotide infusion
Study: 39241828
Drug: 24-hr octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hr octreotide infusion
Study: 39241904
Drug: Etonogestrel implant
Normalized name: Etonogestrel Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etonogestrel implant + oral levonorgestrel (LNG)
Study: 39241904
Drug: 52 mg
Normalized name: papain 52 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 mg levonorgestrel IUD
Study: 39242054
Drug: Low-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interleukin-2 (IL-2), dosage and duration not specified
Study: 39242247
Drug: Hypofractionated radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiotherapy with focal boosts (60Gy in 20 fractions, boost dose up to 68Gy)
Study: 39242497
Drug: 30-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-day treatment with low-molecular weight heparin (dosage not specified)
Study: 39242497
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of 5000 IU low-molecular weight heparin daily from surgery until discharge (approximately 10 days)
Study: 39242497
Drug: 30-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-day treatment with low-molecular weight heparin
Study: 39242497
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of 5000 IU low-molecular weight heparin
Study: 39242499
Drug: Dexmedetomidine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine nasal spray (30 µg or 50 µg based on body weight)
Study: 39242499
Drug: Dexmedetomidine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine nasal spray
Study: 39242877
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml crystalloid fluid bolus (FB)
Study: 39243031
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment with unrestricted mask-access (34 different masks)
Study: 39243058
Drug: Formulation-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation-based cognitive behavioral therapy (CBT)
Study: 39243058
Drug: General offender
Approvals — FDA: no, EMA: no, PMDA: no
Description: General offender treatment program
Study: 39243264
Drug: T-TEER with
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-TEER with the TriClip implant
Study: 39243311
Drug: Ruxolitinib (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (35 mg twice daily, days -15 to -10) and decitabine (20 mg/m² daily, days -10 to -5) plus modified busulfan-cyclophosphamide (mBu/Cy) conditioning regimen
Study: 39243886
Drug: Medium-dose ExPEC10V
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose ExPEC10V (n=8)
Study: 39243886
Drug: High-dose ExPEC10V
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ExPEC10V (n=8)
Study: 39243886
Drug: Pooled ExPEC10V
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled ExPEC10V group (medium- and high-dose)
Study: 39243886
Drug: ExPEC10V (medium-
Approvals — FDA: no, EMA: no, PMDA: no
Description: ExPEC10V (medium- and high-doses)
Study: 39243886
Drug: ExPEC10V medium-dose
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ExPEC10V medium-dose
Study: 39243886
Drug: ExPEC10V high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ExPEC10V high-dose
Study: 39244209
Drug: Niraparib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib plus Bevacizumab first-line maintenance therapy
Study: 39244490
Drug: SHJ002 ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHJ002 ophthalmic solution (0.025%, 0.08%, and 0.25%)
Study: 39244490
Drug: SHJ002 ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHJ002 ophthalmic solution (0.25%)
Study: 39244532
Drug: SOC + ablative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC + ablative therapy (SABR preferred)
Study: 39244532
Drug: SOC palliative-intent
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC palliative-intent treatments
Study: 39244595
Drug: TCZ (Tocilizumab)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TCZ (Tocilizumab) 8 mg/kg every 4 weeks to week 48
Study: 39244893
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet treatment (DAPT)
Study: 39245053
Drug: 10% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% aqueous povidone-iodine for skin preparation
Study: 39245053
Drug: 2% alcoholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% alcoholic chlorhexidine for skin preparation
Study: 39245055
Drug: mRNA-1012 (pentavalent;
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1012 (pentavalent; B/Yamagata replaced with two additional A/H3N2 strains [Newcastle and Hong Kong]) at 50.0 μg
Study: 39245055
Drug: mRNA-1012 (pentavalent;
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1012 (pentavalent; B/Yamagata replaced with two additional A/H3N2 strains [Newcastle and Hong Kong]) at 62.5 μg
Study: 39245341
Drug: Hybrid combination
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid combination of ProGlide (PP) and Angio-Seal (AS)
Study: 39245360
Drug: Cemiplimab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemiplimab (3 mg/kg intravenously every 2 weeks) for groups 1 and 2
Study: 39245360
Drug: Cemiplimab (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemiplimab (350 mg intravenously every 3 weeks) for groups 3 and 6
Study: 39245360
Drug: Serious treatment-emergent
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serious treatment-emergent adverse events (grade ≥3) for groups 1-3
Study: 39245360
Drug: Serious treatment-emergent
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serious treatment-emergent adverse events (grade ≥3) for group 6
Study: 39245584
Drug: Pneumococcal Polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal Polysaccharide vaccine (PPSV23)